Fluticasone-Salmeterol Drug Combination (Advair)

A drug combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Also Known As:

Advair; Seretide; Advair Diskus; Advair HFA; Fluticasone - Salmeterol; Fluticasone Propionate - Salmeterol; Fluticasone Propionate - Salmeterol Combination; Fluticasone Propionate - Salmeterol Xinafoate; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Fluticasone Propionate-Salmeterol Drug Combination; Fluticasone Propionate-Salmeterol Xinafoate Combination; Fluticasone Propionate-Salmeterol Xinafoate Drug Combination; Fluticasone-Salmeterol Combination; Combination, Fluticasone-Salmeterol; Drug Combination, Fluticasone-Salmeterol; Fluticasone Propionate Salmeterol; Fluticasone Propionate Salmeterol Combination; Fluticasone Propionate Salmeterol Drug Combination; Fluticasone Propionate Salmeterol Xinafoate; Fluticasone Propionate Salmeterol Xinafoate Combination; Fluticasone Propionate Salmeterol Xinafoate Drug Combination; Fluticasone Salmeterol; Fluticasone Salmeterol Combination; Fluticasone Salmeterol Drug Combination

Networked: 333 relevant articles (28 outcomes, 113 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Stanford, Richard H: 16 articles (01/2021 - 06/2007)
2.	Dalal, Anand A: 14 articles (06/2012 - 01/2009)
3.	Stempel, David A: 10 articles (05/2016 - 03/2008)
4.	Emmett, Amanda: 10 articles (09/2014 - 02/2002)
5.	Blanchette, Christopher M: 10 articles (12/2012 - 06/2007)
6.	Dorinsky, Paul: 9 articles (10/2008 - 02/2002)
7.	Allan, Richard: 7 articles (06/2021 - 12/2019)
8.	Crater, Glenn D: 7 articles (09/2014 - 10/2010)
9.	Delea, Thomas E: 7 articles (01/2014 - 03/2008)
10.	Hagiwara, May: 7 articles (01/2014 - 03/2008)

Related Diseases

1.	Asthma (Bronchial Asthma) 01/01/2019 - "The mean score on the miniAQLQ increased from 5.16 (SD 1.24) at visit 1 to 5.58 (SD 1.20) at visit 2 and 5.82 (SD 1.04) at visit 3. Overall, 42.6% of patients improved by the MCID of ≥0.5. Conclusion: This real-life study suggests that treatment with fluticasone propionate/salmeterol via the Forspiro device can improve asthma symptom control and quality of life." 01/01/2021 - "Adults with asthma (n = 231) were randomly assigned to either the study group (treated for 12 weeks with fluticasone propionate/salmeterol MDI HFA) or a control group (treated for 12 weeks with fluticasone propionate/salmeterol DPI). " 01/01/2020 - "Results: In a CE study of BFC versus fluticasone/salmeterol combinations (FSC) in asthma, BFC users had fewer total exacerbations. " 09/01/2017 - "In a randomized controlled, pragmatic, open-label trial, 225 well-controlled patients with asthma were randomized (1:2) to maintain high-dose fluticasone propionate/salmeterol xinafoate (FP/SAL, 1000/100 μg) or switch to FP/FOR (1000/40 μg) daily for 12 weeks (phase 1). " 04/28/2017 - "Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study."
2.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2019 - "No studies have investigated genetic effects on quality of life (QoL) measurements like improvements in the St George's Respiratory Questionnaire (SGRQ) scores for chronic obstructive pulmonary disease treatments with fluticasone propionate/salmeterol (FSC). " 01/01/2018 - "Methods: A pilot, proof-of-concept, pharmacological study was undertaken in 14 COPD patients on maintenance treatment with inhaled fluticasone propionate/salmeterol (500/50 μg b.i.d.) for at least 8 weeks (visit 1). " 05/01/2013 - "The purpose of this exploratory physiological study was to evaluate the effects of inhaled fluticasone/salmeterol combination (FSC) on sensory and physiological responses to exercise in subjects with mild-to-moderate COPD. " 09/01/2011 - "Prior studies suggest that fluticasone propionate/salmeterol (FSC) may improve cardiovascular outcomes in COPD and we hypothesized that FSC would reduce arterial stiffness in these patients. " 12/01/2010 - "In a large population-based study in the United Kingdom, we estimated the association between fluticasone propionate/salmeterol fixed-dose combination (FSC) and other ICS use and nonvertebral fracture incidence among patients with COPD. "
3.	Obstructive Lung Diseases (Obstructive Lung Disease) 03/01/2002 - "Seretide for obstructive lung disease." 03/01/2002 - "At a time when the prevalence of both asthma and COPD is increasing, Seretide is a valuable step in the management of these common obstructive lung diseases." 11/01/2012 - "Our hypothesis was tested in 114 COPD patients (median age 62.9 years, smoking exposure 45.9 pack-yrs) participating in the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) study, which previously showed an improvement in BHR with fluticasone and fluticasone/salmeterol. " 03/29/2006 - "Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial." 01/01/2020 - "This study evaluated symptom burden and Global Initiative for Obstructive Lung Disease (GOLD) categorization among patients who recently initiated umeclidinium/vilanterol (UMEC/VI; LAMA/LABA) or fluticasone propionate/salmeterol (FP/SAL; ICS/LABA) single-inhaler dual therapy. "
4.	Dyspnea (Shortness of Breath) 05/01/2013 - "Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD." 01/01/2004 - "Fluticasone propionate/salmeterol was more effective than ipratropium bromide/albuterol for improvement in morning pre-dose FEV(1), morning PEF, 6-hour FEV(1) area under the curve (AUC(6)), Transition Dyspnea Index (TDI) focal score, daytime symptom score, night-time awakenings, sleep symptoms, and albuterol-free nights (p < or = 0.013). " 07/01/2005 - "In comparison with either fluticasone or salmeterol alone, the fluticasone/salmeterol combination is associated with statistically greater improvement in spirometric and dyspnea measures; however, the combination is not associated with fewer exacerbations than either fluticasone or salmeterol used by itself. " 01/01/2012 - "Beclomethasone/formoterol - 400/24 mcg/die, in comparison with fluticasone/salmeterol - 500/100 mcg/die significantly reduced air-trapping and dyspnea in COPD patients. " 10/09/2018 - "CASE REPORT A 25-year-old, non-smoking, African American male with a history of moderate asthma and allergic rhinitis treated with fluticasone/salmeterol diskus, albuterol hydrofluoroalkane (HFA) inhaler, and montelukast presented to our clinic complaining of recurrent episodes of acute shortness of breath immediately following each administration of albuterol for 4 weeks. "
5.	Pneumonia (Pneumonitis) 06/01/2013 - "We describe the proper methods to calculate the NNT and, using data from published trials, apply them to evaluate the relative impact of fluticasone-salmeterol treatment on exacerbations and pneumonias in patients with COPD. " 01/01/2023 - "Compared with Advair Diskus use, Wixela Inhub use was associated with a nearly identical incidence of first moderate or severe COPD exacerbation (hazard ratio [HR], 0.97 [95% CI, 0.90 to 1.04]) and first pneumonia hospitalization (HR, 0.99 [CI, 0.86 to 1.15]). " 06/01/2013 - "For the TORCH trial, the NNT is 44 patients treated for 3 years with fluticasone-salmeterol versus salmeterol to prevent one exacerbation compared with 16 patients to induce one pneumonia case. " 01/01/2016 - "Additionally, users of fluticasone/salmeterol, fluticasone, and either fluticasone/salmeterol or fluticasone were more likely to be at a higher risk of pneumonia (OR =1.35, 95% CI =1.28-1.41; OR =1.22, 95% CI =1.10-1.35; and OR =1.33, 95% CI =1.27-1.39, respectively). " 10/26/2015 - "24 treatments were more harmful, including 2 that increased risk of pneumonia versus placebo; fluticasone and fluticasone/salmeterol. "

Related Drugs and Biologics

1.	Fluticasone (Cutivate)
2.	Salmeterol Xinafoate (Serevent)
3.	Formoterol Fumarate (Oxis)
4.	Budesonide (Pulmicort)
5.	Fluticasone-Salmeterol Drug Combination (Advair)
6.	Beclomethasone (Beclometasone)
7.	Steroids
8.	Adrenal Cortex Hormones (Corticosteroids)
9.	Tiotropium Bromide (Spiriva)
10.	Albuterol (Salbutamol)

Related Therapies and Procedures

1.	Therapeutics
2.	Nebulizers and Vaporizers (Inhaler)
3.	Metered Dose Inhalers (Metered Dose Inhaler)
4.	Moxibustion
5.	Aftercare (After-Treatment)